Luke Erber
- Cancer Research top 10%
- Carcinogens and Genotoxicity Assessment 5
- Cancer, Hypoxia, and Metabolism 4
- Geriatrics and Gerontology top 10%
-
- Epigenetics and DNA Methylation 6
- DNA Repair Mechanisms 5
- Ubiquitin and proteasome pathways 4
- Protein Degradation and Inhibitors 3
- Mitochondrial Function and Pathology 2
-
- Advanced Proteomics Techniques and Applications 5
- Journals
- Chemical Research in Toxicology (6 papers)Angewandte Chemie International Edition (2 papers)Oncotarget (2 papers)
- Partner nations
- United StatesChinaSweden
In The Last Decade
Luke Erber
26 papers receiving 708 citations
Peers
Comparison fields: 5 of 89
- Cancer Research 262
- Geriatrics and Gerontology 30
- Molecular Biology 501
- Pulmonary and Respiratory Medicine 204
- Infectious Diseases 68
Countries citing papers authored by Luke Erber
This map shows the geographic impact of Luke Erber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Erber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Erber more than expected).
Fields of papers citing papers by Luke Erber
This network shows the impact of papers produced by Luke Erber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Erber. The network helps show where Luke Erber may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luke Erber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 6 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 2 | |
| 8 | 2021 | 10 | |
| 9 | 2021 | 3 | |
| 10 | 2021 | 5 | |
| 11 | 2020 | 66 | |
| 12 | 2020 | 10 | |
| 13 | 2020 | 16 | |
| 14 | 2020 | 9 | |
| 15 | 2019 | 20 | |
| 16 | 2018 | 112 | |
| 17 | 2018 | 3 | |
| 18 | 2017 | 268 | |
| 19 | 2016 | 26 | |
| 20 | 2013 | 67 |
About Luke Erber
Luke Erber is a scholar working on Cancer Research, Spectroscopy and Molecular Biology, having authored 28 papers that have together received 712 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (6 papers), DNA Repair Mechanisms (5 papers), Advanced Proteomics Techniques and Applications (5 papers), Carcinogens and Genotoxicity Assessment (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Ubiquitin and proteasome pathways (4 papers), Protein Degradation and Inhibitors (3 papers) and Mitochondrial Function and Pathology (2 papers). The work is most often cited by research in Cancer Research (262 citations), Geriatrics and Gerontology (30 citations) and Molecular Biology (501 citations). Luke Erber has collaborated with scholars based in United States, China and Sweden. Frequent co-authors include Yue Chen, Wei Gu, Omid Tavana, Bo Chu, Delin Chen, Richard Baer, L. James Maher, John Smestad, Natalia Tretyakova and Ang Luo. Their work appears in journals such as Chemical Research in Toxicology, Angewandte Chemie International Edition, Oncotarget, ACS Chemical Biology and iScience.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.